Finished
Cytoreductive Prostatectomy in Treating Patients With Newly Diagnosed, Metastatic Prostate Cancer
NCT02458716 · Rutgers, The State University of New Jersey · Updated 8 April 2021
- What is being tested
- Robotic Assisted Radical Prostatectomy; Conventional open retropubic radical prostectomy; Laboratory Biomarker Analysis; Quality-of-Life Assessment; ADT (androgen deprivation therapy) (i.e. leuprolide) plus an androgen receptor inhibitor (i.e. bicalutamide)
- For
- Metastatic Prostate Carcinoma; Metastatic Prostatic Adenocarcinoma; Prostate Carcinoma Metastatic to the Bone
- Kind of study
- Tests a treatment or device on volunteers. Phase 1.
- Who can join
- Ages 18 years and older. About 26 people. The full rules are on the registry page.
- Where
- United States (3 sites)
- When
- Starts or started 6 March 2015, ends 14 Jan 2020. Registered 1 June 2015.
- Results
- None posted yet.
In the researchers' words
This phase I trial studies the side effects of cytoreductive prostatectomy in treating patients with newly diagnosed prostate cancer that has spread from the primary site to other places in the body. Cytoreductive prostatectomy is a type of surgery that removes the prostate and as much of the tumor as possible. When combined with hormone therapy, robotic assisted radical prostatectomy (RARP) or conventional open retropubic radical prostatectomy (RRP) may prolong survival in patients with prostate cancer that has spread.
Sites
- City of Hope National Medical Center (COH)Duarte, California, United States
- University of California, Irvine (UCI)Orange, California, United States
- Rutgers Cancer Institute of New JerseyNew Brunswick, New Jersey, United States